Extracorporeal carbon dioxide removal for acute respiratory failure
Closed for comments This consultation ended on at Request commenting lead permission
3 Committee considerations
The evidence
3.1 NICE did a rapid review of the published literature on the efficacy and safety of this procedure. This comprised a comprehensive literature search incorporating literature published since the last interventional procedures guidance on this procedure and a detailed review of the evidence from 9 sources, which was discussed by the committee. The evidence included 2 systematic reviews and meta-analyses, 3 randomised controlled trials (RCTs), a long-term follow-up analysis of 1 of the RCTs, 2 case series, and a secondary analysis of 1 of the case series. It is presented in the summary of key evidence section in the interventional procedures overview. Other relevant literature is in the appendix of the overview.
3.2 The professional experts and the committee considered the key efficacy outcomes to be: mortality, reduction in hospital length of stay, reduction in intensive care unit length of stay, and reduction in duration of ventilation.
3.3 The professional experts and the committee considered the key safety outcomes to be: bleeding, intracranial bleeding, infection, and cannulation complications.
3.4 Patient commentary was sought but none was received.
Committee comments
3.5 The committee was informed that the use of arteriovenous extracorporeal carbon dioxide removal (ECCO2R) is largely being replaced by venovenous ECCO2R in the UK.
3.6 The committee noted that there are ongoing clinical trials into the use of ECCO2R for acute hypercapnic respiratory failure.
3.7 The committee was informed that implementation of standard care such as non-invasive ventilation is variable across centres.
Tom Clutton-Brock
Chair, interventional procedures advisory committee
May, 2023
ISBN:
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions